DiaMedica Therapeutics progresses DM199 for ischemic stroke and preeclampsia, aiming to expand treatment windows. Read why ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Shares in large US and European drugmakers slide, underperforming amid a broad market slump, after President Donald Trump said the US was planning to announce "a major tariff on pharmaceuticals" soon.

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

“Participating in the program provides grad students with training and an opportunity to share their research, practice their ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

Investors are snapping up technology shares such as WiseTech and others in energy and healthcare, but remain cautious on ...

Australian shares tumbled nearly 2% on Wednesday, losing $34.5 billion in market value as a global sell-off resumed due to ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants. | Looking to ...

29-year-old entrepreneur Dryden Brown secures massive funding for futuristic city-state Praxis. The project aims to blend ...

White House clarifies that the 125% tariffs are in addition to earlier 20% levies applied for fentanyl trafficking ...